24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

NCT02579252 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL: AADvac1
DRUG: Placebo

Sponsor

Axon Neuroscience SE